Overview

Long Term Safety of Aliskiren Alone or With the Optional Addition of Hydrochlorothiazide in Patients With Essential Hypertension

Status:
Completed

Trial end date:
2005-10-01

Target enrollment:

Participant gender:

Summary

Assess the long-term safety and tolerability of aliskiren, with the optional addition of HCTZ, in patients with essential hypertension, to ensure long term blood pressure control and protect against end organ damage.

Phase:

Phase 3

Details

Lead Sponsor:

Novartis

Treatments:

Hydrochlorothiazide